

Express Mail No.: **EV 452 776 728 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Donald J. KYLE et al.

Confirmation No.: 8122

Application No.: 10/625,708

Group Art Unit: 1624

Filed: July 24, 2003

Examiner: Kahsay Habte, Ph.D.

Title: THERAPEUTIC AGENTS USEFUL
FOR TREATING PAIN

Attorney Docket No.: 6750-174-999
(CAM No.: 305158-999172)

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A27**, **B14**, **B15** and **C32** through **C40**, which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." This Supplemental Information Disclosure Statement supplements the Information Disclosure Statement filed on October 5, 2005.

Legible copies of references **B14**, **B15** and **C32** through **C40** are submitted herewith. Applicants respectfully point out that reference **B15** has an English language portion on pages 20-63 thereof. Also submitted with reference **B15** is an English language abstract. Applicants also point out that reference **C33**, obtained from the National Translations Center, is an English language translation of reference **C32**.

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), a copy of reference **A27**, being a United States Patent Application Publication, is not submitted herewith but will be submitted if requested by the Office.

No admission is made that the information cited in this Supplemental Information Disclosure Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§ 1.97(g) and (h).

Applicants request that the Examiner review all the references identified on the attached Form PTO-1449, and that they be made of record in the file history of the above-identified application.

This Supplemental Information Disclosure Statement is filed under 37 C.F.R. § 1.97(c) after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311 or an action that otherwise closes prosecution in the application. The \$180.00 fee set forth in 37 C.F.R. § 1.17(p) in accordance with 37 C.F.R. § 1.97(c) and any required fee is to be charged to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: February 16, 2006

*Samuel B. Abrams by
Angel A. Smith 42,140*

Samuel B. Abrams

(Reg. No. 30,605)


JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. 6750-174-999 (CAM No. 305158-999172)	APPLICATION NO. 10/625,708
APPLICANT: Donald J. KYLE et al.	
FILING DATE: July 24, 2003	ART UNIT: CONF. NO.: 1624 8122

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A27	2004/0259931 A1	12/23/2004	Goodfellow et al.	
	A28				

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION
						YES NO
	B14	WO 00/39117	07/06/2000	Eli Lilly and Company		
	B15	JP 2003192673	07/09/2003	Bayer AG		XXX
	B16					

NON PATENT LITERATURE DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.
	C32	SOLYOM et al., "Thiokarbamidderivate mit tuberkulostatischer wirkung, I Verbindungen mit heterocyklischem thiokarbamidskelett," <i>Acta Chimical Academiae Scientarum Hungaricae, Tomus 68</i> (1-2):99-132 (1971)
	C33	SOLYOM et al., "Thiocarbamide derivatives with tuberculostatic action, I Compounds with heterocyclic thiocarbamide skeleton," <i>Acta Chimical Academiae Scientarum Hungaricae, Tomus 68</i> (1-2):99-132 (1971); English translation of C32 obtained from National Translations Center
	C34	WRIGGLESWORTH et al., "Capsaicin-like Agonists," <i>Drugs of the Future 23</i> (5):531-538 (1998)
	C35	SZALLASI et al., "Vanilloid (Capsaicin) Receptors and Mechanisma," <i>Pharmacol. Revs. 51</i> (2):159-211 (1999)
	C36	SZALLASI et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," <i>Molec. Pharmacol. 56</i> :581-587 (1999)
	C37	BEVAN et al., "Vanilloid Receptors: Pivotal Molecules in Nociception," <i>Current Opinions in CPNS Investigational Drugs, 2</i> (2):178-185 (2000)
	C38	WANG et al., "High Affinity Antagonists of the Vanilloid Receptor," <i>Mol. Pharmacol. 62</i> (4):947-956 (2002)
	C39	LOPEZ-RODRIGUEZ et al., "VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain," <i>Mini-Revs in Medicinal Chem. 3</i> (7):729-748 (2003)
	C40	POMONIS et al., "N-(4-Tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain," <i>J. Pharmacol. Exper. Therapeutics 306</i> (1):387-393 (2003)
	C41	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.